Skip Ribbon Commands
Skip to main content

Publications

Below is a list of citations of original articles pertaining to research that was conducted as part of the Collaboration for AIDS Vaccine Discovery.
Please click on the title to see more information about the article, read its abstract, and link to the article’s record in PubMed.

In January 2015, the Bill & Melinda Gates Foundation adopted an Open Access policy that enables the unrestricted access and reuse of all peer-
reviewed published research funded, in whole or in part, by the foundation, including any underlying data sets. The action stems from the
commitment to information sharing and transparency.
Learn more here...

  
  
  
  
  
  
  
Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal centerEslamizar LNature Research Journals20211/25/202133495459Link to full-text
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity.Liu, HScience Direct202012/1/2020PMIDLink to full-text
Neutralizing antibody responses induced by HIV-1 envelope glycoprotein SOSIP trimers derived from elite neutralizersSchorcht AJournal of Virology 11/23/202032999024Link to full-text
Visualization of the HIV-1 Env glycan shield across scalesBerndsen ZTProc Natl Acad Sci U S A202011/20/202033093196Link to full-text
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.Philip J. M. BrouwerCell202011/7/2020PMIDLink to full-text
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-glycan patch. Wang ZeLife202010/21/202033084569Link to full-text
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding DomainTom G. CanielsCell reports202010/20/202013619888Link to full-text
Mapping Neutralizing Antibody Epitope Specificities to an HIV Env Trimer in Immunized and in Infected Rhesus MacaquesZhao, FCell Reports20209/8/20202905766Link to full-text
SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight HeparinsBermejo-Jambrina MCell20208/18/2020PMIDLink to full-text
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerabilityPhilip J. M. BrouwerScience20208/7/202013161898Link to full-text
Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and DeletionsMarit J. van GilsStructure (London, England20208/4/202011924992Link to full-text
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigensPhilip J. M. BrouwereLife20208/4/202012692059Link to full-text
Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primatesJelle van SchootenPLoS pathogens20208/1/202013277733Link to full-text
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogensPhilip J. M. BrouwerPLoS pathogens20208/1/202012775937Link to full-text
Structures of Human Antibodies Bound to SARS- CoV-2 Spike Reveal Common Epitopes and Recurrent Features of AntibodiesBarnes COCell20206/24/202032645326Link to full-text
3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Kasturi, S.P.Science Immunology20206/19/202032561559Link to full-text
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal modelRogers TFScience20206/15/202032540903Link to full-text
HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersiteMarit J. van GilsScience advances20206/1/202012050128Link to full-text
Structural basis of broad HIV neutralization by a vaccine-induced cow antibodyStanfield RLScience Advances20205/27/202032518821Link to full-text
Vulnerabilities in coronavirus glycan shields despite extensive glycosylationWatanabe YNature20205/27/202032461612Link to full-text
Variability of CD4+ Cell Counts in HIV-1-Uninfected Volunteers Who Are Eligible for a Phase I HIV Vaccine StudySajadi MMJournal of Acquired Immune Deficiency Syndromes20205/1/202031985697Link to full-text
Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Stephenson, K.E. Annual Reviews of Immunology20204/26/202032340576Link to full-text
VSV-displayed HIV-1 envelope identifies broadly neutralizing antibodies class-switched to IgG and IgA. Jia, M.Cell Host Microbe20204/15/202032315598Link to full-text
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?Klasse PJCell Host & Microbe20204/8/202032272076Link to full-text
Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in RabbitsMarit J. van GilsJournal of virology20204/1/202011248645Link to full-text
Estimating the timing of early Simian-Human Immunodeficiency Virus infections: a comparison between Poisson Fitter and Beast. Giorgi, E.E. mBio20203/24/202032209678Link to full-text
Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in RabbitsYang YRJournal of Virology20203/17/2020Link to full-text
Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticityLai, J.I.Vaccine20203/16/202032192810Link to full-text
Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisitionGorini GiacomoPlos Pathogens20203/12/2020PMC7093029 Link to full-text
Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding LectinRogier W. SandersJournal of virology20203/1/202011128617Link to full-text
1 - 30Next